Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cost of Revenue: 2012-2024

Historic Cost of Revenue for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $358.1 million.

  • Amphastar Pharmaceuticals' Cost of Revenue rose 4.39% to $93.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $366.3 million, marking a year-over-year increase of 7.66%. This contributed to the annual value of $358.1 million for FY2024, which is 22.11% up from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Cost of Revenue stood at $358.1 million, which was up 22.11% from $293.3 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Cost of Revenue ranged from a high of $358.1 million in FY2024 and a low of $206.5 million during FY2020.
  • For the 3-year period, Amphastar Pharmaceuticals' Cost of Revenue averaged around $300.5 million, with its median value being $293.3 million (2023).
  • Data for Amphastar Pharmaceuticals' Cost of Revenue shows a peak YoY grew of 22.11% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Cost of Revenue stood at $206.5 million in 2020, then rose by 15.26% to $238.0 million in 2021, then rose by 5.08% to $250.1 million in 2022, then grew by 17.25% to $293.3 million in 2023, then increased by 22.11% to $358.1 million in 2024.